Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia

被引：0

作者：

Victor Pope

Cyrus C. Hsia

机构：

[1] Western University,Department of Medicine, Schulich School of Medicine and Dentistry

[2] London Health Sciences Centre,Department of Medicine, Division of Hematology,

来源：

Annals of Hematology | 2024年 / 103卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：677 / 679

页数：2

共 7 条

[1]

Khumbanonda M(1969)Coombs’ positive hemolytic Anemia in myelofibrosis with myeloid metaplasia Am J Med Sci 258 89-93

[2]

Horowitz HI(1967)Chronic myelogenous Leukemia with myelofibrosis: four years after auto-immune hemolytic Anemia Arch Intern Med 119 620-625

[3]

Eyster ME(2017)Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation J Allergy Clin Immun 139 1629-1640e2

[4]

Cohen SM(2021)Stepwise reversal of Immune Dysregulation due to STAT1 gain-of-function mutation following Ruxolitinib Bridge therapy and transplantation J Clin Immunol 41 769-779

[5]

Weinacht KG(2020)Successful management of SARS-CoV-2 acute respiratory distress syndrome and newly diagnosed acute lymphoblastic Leukemia Blood Adv 4 4358-4361

[6]

Kayaoglu B(undefined)undefined undefined undefined undefined-undefined

[7]

Phillips L(undefined)undefined undefined undefined undefined-undefined

← 1 →